Adalimumab (Humira™): A promising monoclonal anti-tumor necrosis factor alpha in ophthalmology

被引：48
作者：
Neri P. [1 ,2 ,5 ]
Zucchi M. [3 ]
Allegri P. [4 ]
Lettieri M. [1 ,2 ]
Mariotti C. [1 ,2 ]
Giovannini A. [1 ,2 ]
机构：
[1] Eye Clinic, Azienda Ospedaliera, Universitaria-Ospedali Riuniti di Ancona, Ancona
[2] Ophthalmology Section, Neuroscience Department, Polytechnic University of Marche, Ancona
[3] Dermatology Clinic, Azienda Ospedaliera, Universitaria-Ospedali Riuniti di Ancona, Ancona
[4] Uveitis Center, Ophthalmology Department, Lavagna Hospital, Genoa
[5] Clinica Oculistica, Azienda Ospedaliera, Universitaria-Ospedali Riuniti di Ancona, 60100 Torrette-Ancona
来源：
International Ophthalmology | 2011年 / 31卷 / 2期
关键词：
Adalimumab; Immunosuppression; Macular oedema; Uveitis;
D O I：
10.1007/s10792-011-9430-3
中图分类号：
学科分类号：
摘要：
Tumor necrosis factor alpha (TNF-α) is a key soluble mediator involved in the inflammatory cascade of many disorders including uveitis. Among the anti-TNF-α agents, one of the most used in immune-mediated diseases, such as inflammatory arthropathies, is adalimumab (Humira ™, Abbott Pharmaceutical Inc.), a fully humanized antibody. The purpose of this review is to analyze the main pharmacological and clinical aspects of adalimumab and its efficacy both in systemic and ocular inflammatory disorders. Adalimumab was effective in treating several autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis. In recent years, adalimumab has been used successfully in refractory cases of intraocular inflammation. Moreover, this biological agent showed good safety and efficacy profiles in ocular use including childhood uveitis. Switching from other anti-TNF-α agents to adalimumab may offer several advantages, such as easier administration, better patient compliance, and lower rate of adverse events. Adalimumab is a promising drug for the therapy of uveitis, although further studies are needed on its application in uveitis. © Springer Science+Business Media B.V. 2011.
引用
收藏
页码：165 / 173
页数：8
相关论文
共 52 条
[11]  
Ahn J.K., Yu H.G., Chung H., Park Y.G., Intraocular cytokine environment in active Behçet uveitis, Am J Ophthalmol, 142, 3, pp. 429-434, (2006)
[12]  
Kramer M., Goldenberg-Cohen N., Axer-Siegel R., Weinberger D., Cohen Y., Monselise Y., Inflammatory reaction in acute retinal artery occlusion: Cytokine levels in aqueous humor and serum, Ocular Immunology and Inflammation, 13, 4, pp. 305-310, (2005)
[13]  
Perez-Guijo V., Santos-Lacomba M., Sanchez-Hernandez M., Castro-Villegas Mdel C., Gallardo-Galera J.M., Collantes-Estevez E., Tumour necrosis factor-alpha levels in aqueous humour and serum from patients with uveitis: The involvement of HLA-B27, Curr Med Res Opin, 20, 2, pp. 155-157, (2004)
[14]  
Xu Y., Chen W., Lu H., Hu X., Li S., Wang J., Zhao L., The expression of cytokines in the aqueous humor and serum during endotoxin-induced uveitis in C3H/HeN mice, Mol Vis, 16, pp. 1689-1695, (2010)
[15]  
Feldmann M., Brennan F.M., Maini R.N., Role of cytokines in rheumatoid arthritis, Annual Review of Immunology, 14, pp. 397-440, (1996)
[16]  
Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., Van Hogezand R.A., Podolsky D.K., Sands B.E., Braakman T., Dewoody K.L., Schaible T.F., Van Deventer S.J.H., Infliximab for the treatment of fistulas in patients with Crohn's disease, New England Journal of Medicine, 340, 18, pp. 1398-1405, (1999)
[17]  
Weinblatt M.E., Kremer J.M., Bankhurst A.D., Bulpitt K.J., Fleischmann R.M., Fox R.I., Jackson C.G., Lange M., Burge D.J., A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, New England Journal of Medicine, 340, 4, pp. 253-259, (1999)
[18]  
Lim L.L., Fraunfelder F.W., Rosenbaum J.T., Do tumor necrosis factor inhibitors cause uveitis? A registry-based study, Arthritis and Rheumatism, 56, 10, pp. 3248-3252, (2007)
[19]  
Dick A.D., Duncan L., Hale G., Waldmann H., Isaacs J., Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis, Journal of Autoimmunity, 11, 3, pp. 255-264, (1998)
[20]  
Yue C., You X., Zhao L., Et al., The effects of adalimumab and methotrexate treatment on peripheral Th17 cells and IL-17/IL-6 secretion in rheumatoid arthritis patients, Rheumatol Int, 30, 12, pp. 1553-1557, (2010)
123456